Evoke Pharma, Inc. (EVOK)

Evoke Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-7.79	-8.22	-8.54	-13.15	-7.13
Depreciation & Amortization	0.13	0.04	0	0	0
Share-Based Compensation	1.13	1.46	1.88	1.63	1.37
Other Operating Activities	1.55	0.13	-5.69	4.9	-0.01
Operating Cash Flow	-4.98	-6.6	-12.35	-6.63	-5.76
Share Issuance / Repurchase	0	7.44	13.44	3.93	6.11
Debt Issued / Paid	0	0	0	5.1	0
Other Financing Activities	-0.12	-0.15	-0.01	-	-
Financing Cash Flow	-0.12	7.29	13.43	9.04	6.11
Net Cash Flow	-5.1	0.7	1.08	2.41	0.34
Free Cash Flow	-4.98	-6.6	-12.35	-6.63	-5.76
Free Cash Flow Margin	-96.22%	-262.93%	-763.43%	-28801.07%	-
Free Cash Flow Per Share	-1.49	-2.10	-4.61	-3.12	-3.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).